Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Core Insights - Eli Lilly and Company has reached an agreement with the U.S. government to enhance access to its obesity medications, specifically Zepbound and orforglipron, for Medicare beneficiaries at a cost of $50 per month, pending FDA approval [1][5] - This initiative aims to support nearly 40 million Americans with obesity on government insurance programs, addressing a significant health risk associated with over 200 diseases [1][4] Group 1: Agreement Details - The agreement builds on Lilly's previous collaboration with the Trump Administration, which included capping out-of-pocket insulin costs at $35 per month [1][2] - Lilly will receive three years of tariff relief and will not be subject to future pricing mandates in exchange for addressing the Administration's priorities, including a balanced pricing approach for new medicines [4][5] - The company is investing over $50 billion in U.S. manufacturing to enhance domestic production capabilities [4] Group 2: Product Pricing and Access - Starting April 1, 2026, Zepbound will be available for Medicare beneficiaries at a maximum of $50 per month, with orforglipron also priced similarly, contingent on FDA approval [5] - Zepbound will be priced at $299 for the lowest dose, with additional doses up to $449, reflecting a $50 discount from current prices [5] - Orforglipron will start at $149 for the lowest dose, with higher doses priced up to $399 [5] Group 3: Broader Impact - The agreement is expected to significantly improve access to obesity treatments, which are crucial for managing health risks associated with obesity [2][4] - LillyDirect will facilitate access for self-pay patients, offering additional medications at reduced prices [5] - The initiative aligns with Lilly's commitment to affordability and innovation in healthcare [2][4]